Doxorubicin

Generic Name: Doxorubicin

Brand Names: Adriamycin, Doxil, Myocet, Caelyx pegylated liposomal, Zolsketil pegylated liposomal, Myocet liposomal (previously Myocet), Celdoxome pegylated liposomal

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₂₉NO_₁₁

CAS Number: 23214-92-8

Unique Ingredient Identifier: 80168379AG

Background: Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970. Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its deta...

Indication: Doxorubicin is indicated for the treatment of neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin and non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue and bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinom...

Associated Conditions: AIDS-related Kaposi's Sarcoma, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Advanced Endometrial Cancer, Advanced Ovarian Cancer, Breast Cancer, Hodgkin's Lymphoma, Metastatic Bone Sarcomas, Metastatic Breast Cancer, Metastatic Soft Tissue Sarcoma, Metastatic Thyroid Cancer, Metastatic Urothelial Cancer, Multiple Myeloma (MM), Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Sezary Syndrome, Waldenström's Macroglobulinemia (WM), Advanced Thymoma, Advanced uterine sarcoma, Metastatic Bronchogenic Carcinoma, Metastatic Gastric carcinoma, Metastatic Neuroblastoma, Metastatic Ovarian carcinoma, Metastatic Wilms' tumor

Associated Therapies: -

Clinical Trials

Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: filgrastim
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: paclitaxel
Drug: tamoxifen citrate
Procedure: adjuvant therapy
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2012-10-02

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 16

Registration Number: NCT00007904

Locations: 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
UH-LUICC, Mentor, Ohio, United States
🇺🇸
UH-Chagrin Highlands, Orange Village, Ohio, United States

Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer

Phase 2

Completed

Conditions: Endometrial Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2012-09-24

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 141

Registration Number: NCT00052312

Locations: 🇧🇪
Universitair Ziekenhuis Antwerpen, Edegem, Belgium
🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸
Instituto Valenciano De Oncologia, Valencia, Spain

and more 32 locations

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2012-05-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 400

Registration Number: NCT00003215

Locations: 🇨🇭
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
🇨🇭
Inselspital, Bern, Bern, Switzerland
🇨🇭
Ratisches Kantons und Regionalspital, Chur, Switzerland

and more 9 locations

Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma

Phase 2

Completed

Conditions: Metastatic Osteosarcoma

Interventions: Drug: doxorubicin hydrochloride
Drug: cisplatin
Drug: methotrexate
Drug: leucovorin calcium
Biological: filgrastim
Procedure: therapeutic conventional surgery
Radiation: radiation therapy
Drug: etoposide
Drug: ifosfamide
Biological: trastuzumab
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 80

Registration Number: NCT00023998

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: cyclophosphamide
Biological: filgrastim
Drug: doxorubicin
Drug: paclitaxel
Procedure: surgery

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-24

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 399

Registration Number: NCT00016406

Locations: 🇺🇸
Lenoir Memorial Cancer Center, Kinston, North Carolina, United States
🇺🇸
Holland Community Hospital, Holland, Michigan, United States
🇺🇸
Good Samaritan Cancer Center, Puyallup, Washington, United States

and more 309 locations

Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma

Phase 2

Completed

Conditions: Alveolar Childhood Rhabdomyosarcoma
Embryonal Childhood Rhabdomyosarcoma
Embryonal-botryoid Childhood Rhabdomyosarcoma
Previously Treated Childhood Rhabdomyosarcoma
Recurrent Childhood Rhabdomyosarcoma

Interventions: Drug: vincristine sulfate
Drug: irinotecan hydrochloride
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: ifosfamide
Drug: etoposide
Drug: tirapazamine
Biological: filgrastim
Biological: sargramostim
Other: pharmacological study
Other: pharmacogenomic studies
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 150

Registration Number: NCT00025363

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors

Phase 1

Completed

Conditions: Cardiac Toxicity
Unspecified Childhood Solid Tumor, Protocol Specific

Interventions: Biological: oblimersen sodium
Drug: dexrazoxane hydrochloride
Drug: doxorubicin hydrochloride
Drug: cyclophosphamide
Biological: filgrastim
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT00039481

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Not Applicable

Completed

Conditions: T-cell Childhood Acute Lymphoblastic Leukemia
Untreated Childhood Acute Lymphoblastic Leukemia

Interventions: Drug: prednisone
Drug: vincristine sulfate
Drug: daunorubicin hydrochloride
Drug: asparaginase
Drug: methotrexate
Drug: cyclophosphamide
Drug: cytarabine
Drug: mercaptopurine
Drug: leucovorin calcium
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: thioguanine
Radiation: radiation therapy
Drug: pegaspargase
Other: pharmacological study
Drug: nelarabine
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 100

Registration Number: NCT00016302

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer

Phase 3

Completed

Conditions: Liver Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-26

Lead Sponsor: Eximias Pharmaceutical

Registration Number: NCT00012324

Locations: 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸
Oncology-Hematology Group of South Florida, P.A., Miami, Florida, United States

and more 39 locations

Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer

Phase 2

Conditions: Malignant Mesothelioma

First Posted Date: 2003-01-27

Last Posted Date: 2014-01-06

Lead Sponsor: Herbert Irving Comprehensive Cancer Center

Registration Number: NCT00024271

Locations: 🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy